Citadel Advisors
PRQR icon

Citadel Advisors’s ProQR Therapeutics PRQR Stock Holding History

Citadel Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,200
Closed -$69.1K – 13968
2025
Q4 		$69.1K Buy
+34,200
New +$79.9K ﹤0.01% 11876
2025
Q2 		– Sell
-3,600
Closed -$4.79K – 14541
2025
Q1 		$4.79K Sell
3,600
-17,400
-83% -$37K ﹤0.01% 13863
2024
Q4 		$55.6K Buy
21,000
+20,700
+6,900% +$65.7K ﹤0.01% 12278
2024
Q3 		$546 Sell
300
-1,500
-83% -$2.82K ﹤0.01% 13999
2024
Q2 		$2.99K Sell
1,800
-34,200
-95% -$66.4K ﹤0.01% 13635
2024
Q1 		$81.7K Buy
36,000
+12,600
+54% +$26.9K ﹤0.01% 11627
2023
Q4 		$46.3K Buy
+23,400
New +$36K ﹤0.01% 11853
2023
Q3 		– Sell
-52,900
Closed -$85.7K – 14922
2023
Q2 		$85.7K Sell
52,900
-2,400
-4% -$4.69K ﹤0.01% 11153
2023
Q1 		$118K Buy
55,300
+36,200
+190% +$111K ﹤0.01% 11028
2022
Q4 		$70.7K Sell
19,100
-2,000
-9% -$2.62K ﹤0.01% 11691
2022
Q3 		$16K Sell
21,100
-26,100
-55% -$21K ﹤0.01% 12148
2022
Q2 		$37K Buy
47,200
+16,200
+52% +$12.1K ﹤0.01% 12113
2022
Q1 		$28K Buy
31,000
+4,700
+18% +$15.7K ﹤0.01% 13131
2021
Q4 		$211K Sell
26,300
-28,400
-52% -$216K ﹤0.01% 11742
2021
Q3 		$458K Buy
54,700
+24,700
+82% +$161K ﹤0.01% 10088
2021
Q2 		$202K Sell
30,000
-13,000
-30% -$83.8K ﹤0.01% 12138
2021
Q1 		$284K Buy
+43,000
New +$220K ﹤0.01% 10986
2020
Q3 		– Sell
-21,600
Closed -$131K – 10599
2020
Q2 		$131K Buy
21,600
+7,600
+54% +$41.1K ﹤0.01% 8835
2020
Q1 		$77K Buy
+14,000
New +$107K ﹤0.01% 8809

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Citadel Advisors's PRQR Position: Q1 2026 in Review

Citadel Advisors increased its ProQR Therapeutics (PRQR) stake by 21% in Q1 2026, buying an estimated $197K and bringing the position to 703,323 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #7364.

Citadel Advisors first reported a position in PRQR in Q3 2014 and has held it in 26 quarters since. The position peaked at $1.87M in Q3 2014. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Citadel Advisors held 703,323 shares of ProQR Therapeutics worth $1.14M as of Q1 2026.
  • Citadel Advisors bought 120,101 ProQR Therapeutics shares in Q1 2026, an estimated $197K.
  • ProQR Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7364 holding.
  • Citadel Advisors first reported a position in ProQR Therapeutics in Q3 2014 and has held it in 26 quarters since.
  • Citadel Advisors's ProQR Therapeutics position peaked at $1.87M in Q3 2014.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.